![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD2 |
Gene summary for CD2 |
![]() |
Gene information | Species | Human | Gene symbol | CD2 | Gene ID | 914 |
Gene name | CD2 molecule | |
Gene Alias | LFA-2 | |
Cytomap | 1p13.1 | |
Gene Type | protein-coding | GO ID | GO:0001766 | UniProtAcc | P06729 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
914 | CD2 | GSM4909317 | Human | Breast | IDC | 5.23e-05 | 1.70e-01 | 0.1355 |
914 | CD2 | M1 | Human | Breast | IDC | 3.01e-40 | 8.10e-01 | 0.1577 |
914 | CD2 | P1 | Human | Breast | IDC | 4.16e-12 | 6.08e-01 | 0.1527 |
914 | CD2 | LZE4T | Human | Esophagus | ESCC | 4.60e-14 | 7.29e-01 | 0.0811 |
914 | CD2 | LZE7T | Human | Esophagus | ESCC | 2.24e-10 | 7.96e-01 | 0.0667 |
914 | CD2 | LZE8T | Human | Esophagus | ESCC | 3.62e-04 | 4.38e-01 | 0.067 |
914 | CD2 | LZE22D1 | Human | Esophagus | HGIN | 3.59e-02 | 2.59e-01 | 0.0595 |
914 | CD2 | LZE24T | Human | Esophagus | ESCC | 4.59e-03 | 1.77e-01 | 0.0596 |
914 | CD2 | LZE6T | Human | Esophagus | ESCC | 3.15e-24 | 1.50e+00 | 0.0845 |
914 | CD2 | C21 | Human | Oral cavity | OSCC | 1.93e-15 | 6.64e-01 | 0.2678 |
914 | CD2 | C30 | Human | Oral cavity | OSCC | 2.02e-06 | 2.12e-01 | 0.3055 |
914 | CD2 | C38 | Human | Oral cavity | OSCC | 6.23e-08 | 1.25e+00 | 0.172 |
914 | CD2 | C46 | Human | Oral cavity | OSCC | 5.10e-05 | 2.47e-01 | 0.1673 |
914 | CD2 | C51 | Human | Oral cavity | OSCC | 1.67e-03 | 1.61e-01 | 0.2674 |
914 | CD2 | C57 | Human | Oral cavity | OSCC | 8.29e-04 | 1.33e-01 | 0.1679 |
914 | CD2 | C06 | Human | Oral cavity | OSCC | 2.51e-03 | 9.88e-01 | 0.2699 |
914 | CD2 | C07 | Human | Oral cavity | OSCC | 1.79e-03 | 3.19e-01 | 0.2491 |
914 | CD2 | LN22 | Human | Oral cavity | OSCC | 2.16e-04 | 7.29e-01 | 0.1733 |
914 | CD2 | LN38 | Human | Oral cavity | OSCC | 2.02e-02 | 6.93e-01 | 0.168 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:01987384 | Colorectum | CRC | cell-cell signaling by wnt | 88/2078 | 446/18723 | 4.85e-08 | 6.04e-06 | 88 |
GO:19038295 | Colorectum | CRC | positive regulation of cellular protein localization | 61/2078 | 276/18723 | 9.59e-08 | 1.17e-05 | 61 |
GO:00315324 | Colorectum | CRC | actin cytoskeleton reorganization | 31/2078 | 107/18723 | 3.36e-07 | 2.83e-05 | 31 |
GO:00457855 | Colorectum | CRC | positive regulation of cell adhesion | 81/2078 | 437/18723 | 2.28e-06 | 1.10e-04 | 81 |
GO:00512225 | Colorectum | CRC | positive regulation of protein transport | 61/2078 | 303/18723 | 2.73e-06 | 1.27e-04 | 61 |
GO:00720733 | Colorectum | CRC | kidney epithelium development | 34/2078 | 136/18723 | 3.87e-06 | 1.63e-04 | 34 |
GO:19049515 | Colorectum | CRC | positive regulation of establishment of protein localization | 62/2078 | 319/18723 | 7.44e-06 | 2.72e-04 | 62 |
GO:00971935 | Colorectum | CRC | intrinsic apoptotic signaling pathway | 57/2078 | 288/18723 | 9.77e-06 | 3.31e-04 | 57 |
GO:00068983 | Colorectum | CRC | receptor-mediated endocytosis | 50/2078 | 244/18723 | 1.27e-05 | 4.08e-04 | 50 |
GO:00160504 | Colorectum | CRC | vesicle organization | 57/2078 | 300/18723 | 3.36e-05 | 8.57e-04 | 57 |
GO:00901505 | Colorectum | CRC | establishment of protein localization to membrane | 51/2078 | 260/18723 | 3.59e-05 | 9.05e-04 | 51 |
GO:00016552 | Colorectum | CRC | urogenital system development | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00719004 | Colorectum | CRC | regulation of protein serine/threonine kinase activity | 65/2078 | 359/18723 | 4.67e-05 | 1.10e-03 | 65 |
GO:00709975 | Colorectum | CRC | neuron death | 65/2078 | 361/18723 | 5.55e-05 | 1.26e-03 | 65 |
GO:00720011 | Colorectum | CRC | renal system development | 56/2078 | 302/18723 | 7.85e-05 | 1.63e-03 | 56 |
GO:00018221 | Colorectum | CRC | kidney development | 54/2078 | 293/18723 | 1.23e-04 | 2.40e-03 | 54 |
GO:00458605 | Colorectum | CRC | positive regulation of protein kinase activity | 67/2078 | 386/18723 | 1.34e-04 | 2.55e-03 | 67 |
GO:19012154 | Colorectum | CRC | negative regulation of neuron death | 41/2078 | 208/18723 | 1.79e-04 | 3.17e-03 | 41 |
GO:19012145 | Colorectum | CRC | regulation of neuron death | 57/2078 | 319/18723 | 1.90e-04 | 3.30e-03 | 57 |
GO:00336745 | Colorectum | CRC | positive regulation of kinase activity | 77/2078 | 467/18723 | 2.42e-04 | 4.00e-03 | 77 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Breast | ADJ |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Breast | ADJ |
PVR | CD226 | PVR_CD226 | PVR | Breast | ADJ |
CD70 | CD27 | CD70_CD27 | CD70 | Breast | ADJ |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Breast | DCIS |
ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Breast | DCIS |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Breast | DCIS |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Breast | IDC |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Cervix | ADJ |
ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Cervix | ADJ |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Cervix | ADJ |
CD70 | CD27 | CD70_CD27 | CD70 | Cervix | ADJ |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Cervix | CC |
ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Cervix | CC |
NECTIN2 | CD226 | NECTIN2_CD226 | NECTIN | Cervix | CC |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Cervix | Healthy |
PTPRC | CD22 | PTPRC_CD22 | CD45 | Cervix | Precancer |
PTPRC | CD22 | PTPRC_CD22 | CD45 | CRC | AD |
CD48 | CD244 | CD48_CD244A | CD48 | CRC | AD |
PTPRC | CD22 | PTPRC_CD22 | CD45 | CRC | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD2 | SNV | Missense_Mutation | c.205N>A | p.Ala69Thr | p.A69T | P06729 | protein_coding | deleterious(0.04) | probably_damaging(0.929) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD2 | SNV | Missense_Mutation | c.150N>C | p.Met50Ile | p.M50I | P06729 | protein_coding | tolerated(0.08) | benign(0.196) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CD2 | SNV | Missense_Mutation | c.776A>C | p.Glu259Ala | p.E259A | P06729 | protein_coding | tolerated(0.06) | possibly_damaging(0.669) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CD2 | SNV | Missense_Mutation | novel | c.420C>G | p.Ile140Met | p.I140M | P06729 | protein_coding | tolerated(0.11) | possibly_damaging(0.687) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CD2 | SNV | Missense_Mutation | c.141T>G | p.Ser47Arg | p.S47R | P06729 | protein_coding | tolerated(0.17) | benign(0.005) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CD2 | SNV | Missense_Mutation | rs769894316 | c.595G>A | p.Glu199Lys | p.E199K | P06729 | protein_coding | tolerated(0.84) | benign(0.001) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CD2 | SNV | Missense_Mutation | c.67N>T | p.Val23Phe | p.V23F | P06729 | protein_coding | tolerated(0.06) | benign(0.086) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CD2 | SNV | Missense_Mutation | c.166N>A | p.Asp56Asn | p.D56N | P06729 | protein_coding | tolerated(0.09) | probably_damaging(0.927) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
CD2 | SNV | Missense_Mutation | c.881N>T | p.Ser294Ile | p.S294I | P06729 | protein_coding | deleterious(0.02) | benign(0.077) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
CD2 | SNV | Missense_Mutation | novel | c.320N>C | p.Val107Ala | p.V107A | P06729 | protein_coding | deleterious(0.05) | possibly_damaging(0.811) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | 178103393 | ALEFACEPT | |
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | ALEFACEPT | ALEFACEPT | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | CHEMBL2108742 | SIPLIZUMAB | |
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | ZNCL2 | 8131214 | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | SMS 201-995 | 7628916 | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | CHEMBL1201571 | ALEFACEPT | |
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | Siplizumab | SIPLIZUMAB | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | TUMOR NECROSIS FACTOR | 1359970 | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | COBALT | 8131214 | ||
914 | CD2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | ALEFACEPT | ALEFACEPT |
Page: 1 2 |